Kineta Immuno-Oncology, LLC.

Drug Discovery    

Kineta Immuno-Oncology is a privately held biotech company focused on developing disruptive technologies that shift the paradigm in cancer treatment by turning cold tumors hot.  Kineta Immuno-oncology was established in 2016.  Our novel technology was originally discovered through the innate immune screening platform developed by Kineta, Inc., and supported by funding from the National Institutes of Health (NIH).

Since investing, Kineta IO has returned over 120% of the original investment in cash distributions to early investors, following signing a $500M strategic development agreement with Pfizer.  Cantilever holds preferred shares in this company.